APOE and Alzheimer disease: With the hope of comparing the patient risk for vascular adverse events in anti-Aβ immunotherapy, we selected an AD transgenic mouse model (APPswe/PS1dE9 [44,45,46,47]) in which murine APOE has been replaced by human APOE4 or human APOE3, and its expression remains controlled by the native murine APOE promoter [48,49].